Key points are not available for this paper at this time.
Among patients with resected esophageal or gastroesophageal junction cancer who had received neoadjuvant chemoradiotherapy, disease-free survival was significantly longer among those who received nivolumab adjuvant therapy than among those who received placebo. (Funded by Bristol Myers Squibb and Ono Pharmaceutical; CheckMate 577 ClinicalTrials.gov number, NCT02743494.).
Building similarity graph...
Analyzing shared references across papers
Loading...
Ronan J. Kelly
Jaffer A. Ajani
Jarosław Kużdżał
New England Journal of Medicine
Capital humano: revista para la integración y desarrollo de los recursos humanos
Johns Hopkins University
University of California, San Francisco
Inserm
Building similarity graph...
Analyzing shared references across papers
Loading...
Kelly et al. (Wed,) studied this question.
www.synapsesocial.com/papers/699562fba5dc7482368983be — DOI: https://doi.org/10.1056/nejmoa2032125
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: